electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Andy Brown as VP, Corporate Controller effective September 9, 2025. As part of his employment package, Brown was granted 10,000 restricted stock units (RSUs) as an inducement award under NASDAQ Listing Rule 5635(c)(4).
The RSUs will vest in three equal installments of 33% each on the first, second, and third anniversaries of the grant date, contingent upon Brown's continued employment. Upon vesting, the RSUs will be converted into shares of electroCore's common stock.
[]electroCore (NASDAQ: ECOR), azienda nel settore della medicina bioelettronica e del benessere, ha nominato Andy Brown vicepresidente e controller aziendale a partire dal 9 settembre 2025. Come parte del pacchetto retributivo, a Brown sono state assegnate 10.000 unità azionarie vincolate (RSU) come premio di incentivo ai sensi della regola di quotazione NASDAQ 5635(c)(4).
Le RSU matureranno in tre tranche uguali del 33% ciascuna nel primo, secondo e terzo anniversario della data di concessione, subordinatamente alla permanenza in servizio di Brown. Alla maturazione, le RSU saranno convertite in azioni ordinarie di electroCore.
electroCore (NASDAQ: ECOR), una empresa de medicina bioelectrónica y bienestar, ha nombrado a Andy Brown vicepresidente y controlador corporativo con efecto a partir del 9 de septiembre de 2025. Como parte de su paquete de empleo, a Brown se le concedieron 10.000 unidades de acciones restringidas (RSU) como un premio por incentivo conforme a la norma de cotización NASDAQ 5635(c)(4).
Las RSU se consolidarán en tres pagos iguales del 33% cada uno en el primer, segundo y tercer aniversario de la fecha de concesión, condicionadas a la continuidad en el empleo de Brown. Al consolidarse, las RSU se convertirán en acciones ordinarias de electroCore.
electroCore (NASDAQ: ECOR)는 생체전기 의학 및 웰니스 기업으로서 앤디 브라운(Andy Brown)을 2025년 9월 9일부로 부사장 겸 법인 재무책임자(VP, Corporate Controller)로 임명했습니다. 고용 패키지의 일환으로 브라운에게는 NASDAQ 상장규정 5635(c)(4)에 따른 유인 보상으로 10,000개의 제한부 주식 단위(RSU)가 부여되었습니다.
해당 RSU는 부여일로부터 1주년, 2주년, 3주년에 각각 33%씩 세 번에 걸쳐 조건부로 취득되며, 이는 브라운의 계속 고용을 전제로 합니다. 취득 시 RSU는 electroCore의 보통주로 전환됩니다.
electroCore (NASDAQ: ECOR), une société de médecine bioélectronique et de bien-être, a nommé Andy Brown au poste de vice‑président et contrôleur d'entreprise, à compter du 9 septembre 2025. Dans le cadre de son contrat, Brown s'est vu attribuer 10 000 unités d'actions restreintes (RSU) en tant que récompense d'incitation conformément à la règle de cotation NASDAQ 5635(c)(4).
Les RSU seront acquises par paliers égaux de 33 % chacun au premier, au deuxième et au troisième anniversaire de la date d'attribution, sous réserve de la poursuite de l'emploi de Brown. À l'acquisition, les RSU seront converties en actions ordinaires d'electroCore.
electroCore (NASDAQ: ECOR), ein Unternehmen für bioelektronische Medizin und Wellness, hat Andy Brown zum Vice President und Corporate Controller mit Wirkung zum 9. September 2025 ernannt. Im Rahmen seines Anstellungsvertrags wurden Brown 10.000 Restricted Stock Units (RSUs) als Anreizgewährung gemäß NASDAQ-Listingregel 5635(c)(4) gewährt.
Die RSUs werden in drei gleichen Tranchen zu je 33% am ersten, zweiten und dritten Jahrestag des Gewährungsdatums vesten, vorbehaltlich Browns fortgesetzter Anstellung. Beim Vesting werden die RSUs in Stammaktien von electroCore umgewandelt.
- None.
- None.
ROCKAWAY, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Andy Brown has joined electroCore, effective September 9, 2025, as the Company’s VP, Corporate Controller. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Brown in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Brown’s commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4).
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
Who is the new VP, Corporate Controller at electroCore (NASDAQ: ECOR)?
What compensation package did electroCore (ECOR) offer to Andy Brown?
How will the RSUs vest for electroCore's new Corporate Controller?
What is electroCore's (ECOR) main business focus?
